References
- Shavlev, Arieh Y. What is posttraumatic stress disorder?' Gun. Bydriatry62\(Suppl. 17), 4–9 (2001).
- •Review of PTSD and patient assessment.
- Voris, JC, Voris CT, Kaltsounis J. Use of nefazodone in the treatment of posttraumatic stress disorder. Veterans Health System 61–65 (2001).
- •Retrospective review showing nefazodone as most frequently selected antidepressant for treating PTSD.
- Watanabe MD, Finley PR. Psychiatric Disarlers. Applied therapeutics the clinical use of drugs; 17th Ed. 74.33-35 (2001).
- Kessler RC. Posttraumatic stress disorder: the burden to the individual and to society. Gun. Psychiatry 61 (Suppl. 5), 4–12 (2000).
- Kessler RC, Sonnega A, Bromet E et al Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry52, 1048–1060 (1995).
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disarlers, Fourth Edition. American Psychiatric Association, Washington, DC, USA (1994).
- Gillin JC, Smith-Vaniz A, Schnierow B et al An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. j Clin. PTchiatry 62 (10), 789–796 (2001). Showed significant improvement in PTSD and depression rating scales.
- Yehuda R. Post-traumatic stress disorder. N Engl. Med. 346, 108–114 (2002).
- Davidson JRT. Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up and predictors of outcome. j Gun. Psychiatry 61 (Suppl. 5), 52 (2000).
- Foa EB, Davidson JRT, Frances A. Expert Consensus Guideline Series. Treatment of posttraumatic stress disorder. j Clin. Psychiatry 60\(Suppl. 16), 6–75 (1999).
- Brady K, Perlstein T, Asnis GM et al Efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAIVIA 283, 1837–1844 (2000).
- Davidson J, Peristein T, Londborg P et al Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled
- •• study. Am. J. Psychiatry 158, 1974–1981 (2001).
- Tucker P, Zaninelli, Yehuda R et al Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Clin. Psychiatry 62,860–868 (2001).
- Marshall RD, Beebe KL, Oldham M et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry 158, 1982–1988 (2001).
- Bristol-Myers Squibb prescribing information package insert for nefazodone (Serzonel .
- Fuller MA, Sajatovic M. Nefazodone. Lexicomp Drug Information for Mental Health. 386–387 (2001).
- Robinson DS, Roberts DL, Smith JM et al. The safety profile of nefazodone. j Clin. fiychiatry57\(Suppl. 2), 31–38 (1996).
- Dunner DL, Laird LK. Comparative safety and tolerability of nefazodone. j Clin. Rychiatry63\(Suppl. 1), 33–41 (2002). Comparison of adverse events with nefazodone and other antidepressants.
- Feiger A, Kiev A, Shrivastava RK et al. Nefazodone versussertraline in out-patients with major depression: focus on efficacy, tolerability and effects on sexual function and satisfaction. J. Clin. Psychiatry 57\(Suppl. 2), 53–62 (1996).
- Ferguson JM, Shrivastava R, Stahl SM et al Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. j Clin. Ptychiatry62, 24–29 (2001).
- Davis LL, Nugent AL, Murray J et al. Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. Clin. Ptychopharmacol 20(2), 159–164 (2000). Significant improvement in CAPS score.
- Zisook S, Chentsova-Dutton YE, Smith- Vaniz A et al Nefazodone in patients with treatment-refractory posttraumatic stress disorder. J. Clin. fiychiatry61 (3), 203–208 (2000). Reported significant improvement in PTSD symptoms.
- Raskind MA, Dobie DJ, Kanter ED et al The al-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J. Clin. Psychiatry 61, 129–133 (2000).
- Rickels K, Schweizer E, Clary C et al Nefazodone and imipramine in major depression: a placebo-controlled trial. BE J. fiychiatry164 (4), 802–805 (1994) .
- Feighner JP, Pambakian R, Fowler RC et al A comparison of nefazodone, imipramine and placebo in patients with moderate to severe depression. Ptychopharmacol Bull 25(2), 219–221 (1989).
- Fontaine R, Ontiveros A, Elie R et al A double-blind comparison of nefazodone, imipramine and placebo in major depression. J. Clin. Ptychiatry55,234–241 (1994).
- Fawcett J, Marcus RN, Anton SF et al Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J. Clin. Ptychiatry56, 37–42 (1995).
- Papp L, Coplan JD, Martinez JM et al Efficacy of open-label nefazodone treatment in patients with panic disorder. J. Clin. Ptychopharmacol 20,544–546 (2000).
- Mellman TA, David D, Barza L. Nefazodone treatment and dream reports in chronic PTSD. Depression Anxiety9, 146–148 (1999).
- Armitage R. Effects of antidepressant treatment on sleep EEG in depression. fiychopharmacol 12\(Suppl. 1), 22–25 (1996).
- Armitage R, Yonkers K, Cole D et al A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed out-patients. j Clin. Psychopharmacol 17,161–168 (1997).
- Rush AJ, Armitage R, Gillen JC et al Comparative effects of nefazodone and fluoxetine on sleep in out-patients with major depression disorder. Biol. Psychiatry 44,3–14 (1998).
- Davidson JRT, Weisler RII, Malik ML et al Treatment of posttraumatic stress disorder with nefazodone. Int. Clin. Psychopharmacol 13(3), 111–113 (1998). Significant improvement in PTSD symptoms within 12 weeks.
- Hertzberg MA, Feldman ME, Beckham JC. Open trial of nefazodone for combat-related posttraumatic stress disorder. J. Clin. Psychiatty 59 (9), 460–464 (1998) .
- Hildago R, Hertzberg MA, Mellman T et al Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int. Clin. Ptychopharmacol 14,61–68 (1999)
- Voris JC, Shaurette GN, Sebastian PS et al Nefazodone single versustwice daily dosing. Pharmacotherapy18(2), 379–380 (1998).